{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:17:58Z","timestamp":1773278278265,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00120-023-02079-4","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T12:02:23Z","timestamp":1685620943000},"page":"640-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Urothelkarzinom des oberen Harntrakts","Urothelial carcinoma of the upper urinary tract"],"prefix":"10.1007","volume":"62","author":[{"given":"Jennifer","family":"Kranz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radu","family":"Alexa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Kuppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine Therese","family":"Gaisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Saar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"issue":"1","key":"2079_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12894-021-00876-7","volume":"21","author":"A Soualhi","year":"2021","unstructured":"Soualhi\u00a0A, Rammant\u00a0E, George\u00a0G, Russell\u00a0B, Enting\u00a0D, Nair\u00a0R, Van Hemelrijck\u00a0M, Bosco\u00a0C (2021) The incidence and prevalence of upper tract urothelial carcinoma: a\u00a0systematic review. BMC Urol 21(1):110. https:\/\/doi.org\/10.1186\/s12894-021-00876-7","journal-title":"BMC Urol"},{"key":"2079_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","volume":"35","author":"F Soria","year":"2017","unstructured":"Soria\u00a0F, Shariat\u00a0SF, Lerner\u00a0SP, Fritsche\u00a0HM, Rink\u00a0M, Kassouf\u00a0W et al (2017) Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 35:379\u2013387","journal-title":"World J Urol"},{"key":"2079_CR3","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1007\/s00345-020-03576-3","volume":"39","author":"B Alm\u00e5s","year":"2021","unstructured":"Alm\u00e5s\u00a0B et\u00a0al (2021) Higher than expected and significantly increasing incidence of upper tract urothelial carcinoma. A population based study. World J Urol 39:3385","journal-title":"World J Urol"},{"key":"2079_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00345-010-0594-7","volume":"29","author":"SF Shariat","year":"2011","unstructured":"Shariat\u00a0SF, Favaretto\u00a0RL, Gupta\u00a0A, Fritsche\u00a0H\u2011M, Matsumoto\u00a0K, Kassouf\u00a0W et al (2011) Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 29:481\u2013486. https:\/\/doi.org\/10.1007\/s00345-010-0594-7","journal-title":"World J Urol"},{"key":"2079_CR5","unstructured":"https:\/\/uroweb.org\/guidelines\/upper-urinary-tract-urothelial-cell-carcinoma\/chapter\/citation-information. Zugegriffen: 08.04.23"},{"key":"2079_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00345-012-0877-2","volume":"31","author":"M Cosentino","year":"2013","unstructured":"Cosentino\u00a0M et\u00a0al (2013) Upper urinary tract urothelial cell carcinoma: location as a\u00a0predictive factor for concomitant bladder carcinoma. World J Urol 31:141","journal-title":"World J Urol"},{"issue":"3","key":"2079_CR7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.ju.0000169424.79702.6d","volume":"174","author":"J Palou","year":"2005","unstructured":"Palou\u00a0J et\u00a0al (2005) Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J\u00a0Urol 174(3):859\u2013618","journal-title":"J Urol"},{"key":"2079_CR8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.eururo.2012.02.042","volume":"61","author":"E Xylinas","year":"2012","unstructured":"Xylinas\u00a0E et\u00a0al (2012) Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol 61:1069","journal-title":"Eur Urol"},{"key":"2079_CR9","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cncr.24135","volume":"115","author":"V Margulis","year":"2009","unstructured":"Margulis\u00a0V et\u00a0al (2009) Outcomes of radical nephroureterectomy: a\u00a0series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115:1224","journal-title":"Cancer"},{"key":"2079_CR10","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.eururo.2013.06.010","volume":"65","author":"JJ Crivelli","year":"2014","unstructured":"Crivelli\u00a0JJ et\u00a0al (2014) Effect of smoking on outcomes of urothelial carcinoma: a\u00a0systematic review of the literature. Eur Urol 65:742","journal-title":"Eur Urol"},{"key":"2079_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.canep.2017.03.002","volume":"48","author":"M Zaitsu","year":"2017","unstructured":"Zaitsu\u00a0M et al (2017) Alcohol consumption and risk of upper-tract urothelial cancer. Cancer Epidemiol 48:36","journal-title":"Cancer Epidemiol"},{"key":"2079_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3389\/fonc.2019.00157","volume":"9","author":"CC Huang","year":"2019","unstructured":"Huang\u00a0CC et al (2019) Gender is a\u00a0significant prognostic factor for upper tract Urothelial carcinoma: a large hospital-based cancer registry study in an endemic area. Front Oncol 9:157","journal-title":"Front Oncol"},{"key":"2079_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.dnarep.2016.05.027","volume":"44","author":"TA Rosenquist","year":"2016","unstructured":"Rosenquist\u00a0TA et\u00a0al (2016) Mutational signature of aristolochic acid: Clue to the recognition of a\u00a0global disease. DNA Repair 44:205","journal-title":"DNA Repair"},{"key":"2079_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.juro.2017.08.002","volume":"199","author":"MJ Metcalfe","year":"2018","unstructured":"Metcalfe\u00a0MJ et\u00a0al (2018) Universal point of care testing for lynch syndrome in patients with upper tract urothelial carcinoma. J\u00a0Urol 199:60","journal-title":"J Urol"},{"key":"2079_CR15","unstructured":"Brierley JD et\u00a0al (2016) TNM Classification of Malignant Tumours. 8th ed. https:\/\/www.uicc.org\/resources\/tnm-classification-malignant-tumours-8thedition. Zugegriffen: 08.04.23"},{"issue":"2","key":"2079_CR16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.euo.2020.12.007","volume":"4","author":"JP Sfakianos","year":"2021","unstructured":"Sfakianos\u00a0JP, Gul\u00a0Z, Shariat\u00a0SF, Matin\u00a0SF, Daneshmand\u00a0S, Plimack\u00a0E, Lerner\u00a0S, Roupret\u00a0M, Pal\u00a0S (2021) Genetic differences between bladder and upper urinary tract carcinoma: implications for therapy. Eur Urol Oncol 4(2):170\u2013179. https:\/\/doi.org\/10.1016\/j.euo.2020.12.007","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"2079_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.eururo.2020.05.039","volume":"78","author":"MR Hassler","year":"2020","unstructured":"Hassler\u00a0MR, Bray\u00a0F, Catto\u00a0JWF, Grollman\u00a0AP, Hartmann\u00a0A, Margulis\u00a0V, Matin\u00a0SF, Roupret\u00a0M, Sfakianos\u00a0JP, Shariat\u00a0SF, Faltas\u00a0BM (2020) Molecular characterization of upper tract Urothelial carcinoma in the era of next-generation sequencing: a systematic review of the current literature. Eur Urol 78(2):209\u2013220. https:\/\/doi.org\/10.1016\/j.eururo.2020.05.039","journal-title":"Eur Urol"},{"issue":"5","key":"2079_CR18","doi-asserted-by":"publisher","first-page":"236.e23","DOI":"10.1016\/j.urolonc.2015.12.002","volume":"34","author":"A Mohapatra","year":"2016","unstructured":"Mohapatra\u00a0A, Vemana\u00a0G, Bhayani\u00a0S, Baty\u00a0J, Vetter\u00a0J, Strope\u00a0SA (2016) Trends in the utilization of imaging for upper tract urothelial carcinoma. Urol Oncol 34(5):236.e23\u2013236.e28. https:\/\/doi.org\/10.1016\/j.urolonc.2015.12.002","journal-title":"Urol Oncol"},{"key":"2079_CR19","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s00345-019-02875-8","volume":"38","author":"F Janisch","year":"2020","unstructured":"Janisch\u00a0F, Shariat\u00a0SF, Baltzer\u00a0P et al (2020) Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a\u00a0systematic review and meta-analysis. World J Urol 38:1165\u20131175. https:\/\/doi.org\/10.1007\/s00345-019-02875-8","journal-title":"World J Urol"},{"issue":"2","key":"2079_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jasc.2021.12.003","volume":"11","author":"EM Wojcik","year":"2022","unstructured":"Wojcik\u00a0EM, Kurtycz\u00a0DFI, Rosenthal\u00a0DL (2022) We\u2019ll always have Paris the Paris system for reporting urinary cytology 2022. J\u00a0Am Soc Cytopathol 11(2):62\u201366. https:\/\/doi.org\/10.1016\/j.jasc.2021.12.003","journal-title":"J Am Soc Cytopathol"},{"key":"2079_CR21","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1464-410X.2010.09899.x","volume":"108","author":"J Messer","year":"2011","unstructured":"Messer\u00a0J, Shariat\u00a0SF, Brien\u00a0JC, Herman\u00a0MP, Ng\u00a0CK, Scherr\u00a0DS et\u00a0al (2011) Urinary cytology has a\u00a0poor performance for predicting invasive or high grade upper tract urothelial carcinoma. BJU Int 108:701\u2013705","journal-title":"BJU Int"},{"issue":"2","key":"2079_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/21681805.2017.1295102","volume":"51","author":"C Malm","year":"2017","unstructured":"Malm\u00a0C et\u00a0al (2017) Diagnostic accuracy of upper tract urothelial carcinoma: how samples are collected matters. Scand J Urol 51(2):137\u2013145","journal-title":"Scand J Urol"},{"key":"2079_CR23","doi-asserted-by":"publisher","first-page":"790738","DOI":"10.3389\/fsurg.2021.790738","volume":"8","author":"FJ Koll","year":"2021","unstructured":"Koll\u00a0FJ et al (2021) Evaluation of pre-operative biopsy, surgical procedures and oncologic outcomes in upper tract urothelial carcinoma (UTUC). Front Surg 8:790738","journal-title":"Front Surg"},{"issue":"7-8","key":"2079_CR24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1159\/000513459","volume":"105","author":"L Eismann","year":"2021","unstructured":"Eismann\u00a0L, Mumm\u00a0JN, Bohn\u00a0L, W\u00fclfing\u00a0C, Kn\u00fcchel-Clarke\u00a0R, Casuscelli\u00a0J, Waidelich\u00a0R, Stief\u00a0CG, Schlenker\u00a0B, Rodler\u00a0S (2021) The impact of fluorescence in situ hybridization on the staging of upper tract urothelial carcinoma. Urol Int 105(7-8):631\u2013636. https:\/\/doi.org\/10.1159\/000513459","journal-title":"Urol Int"},{"key":"2079_CR25","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/JU.0000000000001834","volume":"206","author":"V Sharma","year":"2021","unstructured":"Sharma\u00a0V et al (2021) The impact of upper tract Urothelial carcinoma diagnostic modality on intravesical recurrence after radical nephroureterectomy: a single institution series and updated meta-analysis. J\u00a0Urol 206:558","journal-title":"J Urol"},{"key":"2079_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1089\/end.2014.0551","volume":"29","author":"MT Bus","year":"2015","unstructured":"Bus\u00a0MT et\u00a0al (2015) Optical diagnostics for upper urinary tract urothelial cancer: technology, thresholds, and clinical applications. J\u00a0Endourol 29:113","journal-title":"J Endourol"},{"key":"2079_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrurol.2015.24","volume":"12","author":"T Seisen","year":"2015","unstructured":"Seisen\u00a0T et al (2015) Risk-adapted strategy for the kidney-sparing management of upper tract tumours. Nat Rev Urol 12:155","journal-title":"Nat Rev Urol"},{"issue":"11","key":"2079_CR28","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/j.1464-410X.2012.11066.x","volume":"110","author":"M Grasso","year":"2012","unstructured":"Grasso\u00a0M et al (2012) Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a\u00a015-year comprehensive review of 160\u00a0consecutive patients. BJU Int 110(11):1618\u20131626","journal-title":"BJU Int"},{"issue":"6","key":"2079_CR29","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S1470-2045(20)30147-9","volume":"21","author":"Kleinmann","year":"2020","unstructured":"Kleinmann et al (2020) Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a\u00a0mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol 21(6):776\u2013785","journal-title":"Lancet Oncol"},{"issue":"4","key":"2079_CR30","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.eururo.2011.05.064","volume":"60","author":"T O\u2019Brien","year":"2011","unstructured":"O\u2019Brien\u00a0T et al (2011) Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a\u00a0prospective, multicentre, randomised clinical trial of a\u00a0single postoperative intravesical dose of mitomycin C (the ODMIT\u2011C Trial). Eur Urol 60(4):703\u2013710","journal-title":"Eur Urol"},{"issue":"60","key":"2079_CR31","doi-asserted-by":"publisher","first-page":"101500","DOI":"10.18632\/oncotarget.21551","volume":"8","author":"Y Kubota","year":"2017","unstructured":"Kubota\u00a0Y et\u00a0al (2017) Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a\u00a0multicenter study. Oncotarget 8(60):101500\u2013101508","journal-title":"Oncotarget"},{"issue":"6","key":"2079_CR32","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.euf.2017.03.013","volume":"4","author":"S Hosogoe","year":"2018","unstructured":"Hosogoe\u00a0S et al (2018) Platinum-based neoadjuvant chemotherapy improves oncological outcomes in patients with locally advanced upper tract urothelial carcinoma. Eur Urol Focus 4(6):946\u2013953","journal-title":"Eur Urol Focus"},{"issue":"5","key":"2079_CR33","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/bju.15253","volume":"127","author":"D D\u2019Andrea","year":"2021","unstructured":"D\u2019Andrea\u00a0D et\u00a0al (2021) Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int 127(5):528\u2013537","journal-title":"BJU Int"},{"issue":"3","key":"2079_CR34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/bju.15230","volume":"127","author":"K Zennami","year":"2021","unstructured":"Zennami\u00a0K et al (2021) Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma. BJU Int 127(3):332\u2013339","journal-title":"BJU Int"},{"issue":"6_suppl","key":"2079_CR35","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1200\/JCO.2022.40.6_suppl.440","volume":"40","author":"W Yip","year":"2022","unstructured":"Yip\u00a0W et al (2022) Final results of a\u00a0multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma. J\u00a0Clin Oncol 40(6_suppl):440\u2013440","journal-title":"J Clin Oncol"},{"issue":"10232","key":"2079_CR36","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle\u00a0A et al (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a\u00a0phase 3, open-label, randomised controlled trial. Lancet 395(10232):1268\u20131277","journal-title":"Lancet"},{"key":"2079_CR37","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot\u00a0Y, Necchi\u00a0A, Park\u00a0SH, Garcia-Donas\u00a0J, Huddart\u00a0R, Burgess\u00a0E, Fleming\u00a0M, Rezazadeh\u00a0A, Mellado\u00a0B, Varlamov\u00a0S et al (2019) Erdafitinib in locally advanced or metastatic urothelial carcinoma. N\u00a0Engl J Med 381:338\u2013348. https:\/\/doi.org\/10.1056\/NEJMoa1817323","journal-title":"N Engl J Med"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-023-02079-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-023-02079-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-023-02079-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T14:48:43Z","timestamp":1702565323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-023-02079-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2079"],"URL":"https:\/\/doi.org\/10.1007\/s00120-023-02079-4","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"8 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>J.\u00a0Kranz<\/b>: A.\u00a0Finanzielle Interessen: J.\u00a0Kranz gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Gesch\u00e4ftsf\u00fchrende Ober\u00e4rztin, Klinik f\u00fcr Urologie und Kinderurologie, Uniklinik RWTH Aachen | Mitglied in folgenden wissenschaftlichen Gesellschaften\/Berufsverb\u00e4nden: NRWGU e.\u202fV., DGU e.\u202fV., GeSRU e.\u202fV., DEGUM e.\u202fV., DGRU e.\u202fV., D\u00c4B e.\u202fV.; Mitglied im Arbeitskreis \u201eInfektiologie und Hygiene\u201c, \u201eUrologische Funktionsdiagnostik und Urologie der Frau\u201c, \u201eAkutmedizin\u201c der DGU e.\u202fV.; Mitglied Arbeitsgemeinschaft urologische Forschung; Vorsitzende (gemeinsam mit PD Necknig) der Juniorakademie der DGU e.\u202fV.; AWMF S3 Leitlinie \u201eS3-Leitlinie Epidemiologie, Diagnostik, Therapie, Pr\u00e4vention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten\u201c \u2013 ESIU der EAU; EAU Guideline \u201eUrological Infecktions\u201c. <b>M.\u00a0Hoffmann<\/b>: A.\u00a0Finanzielle Interessen: M.\u00a0Hoffmann gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Forschungslaborleiter, Klinik f\u00fcr Urologie und Kinderurologie der Universit\u00e4t RWTH Aachen. <b>R.\u00a0Alexa<\/b>: A.\u00a0Finanzielle Interessen: R.\u00a0Alexa gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte:r Urologe; Klinik f\u00fcr Urologie und Kinderurologie, Uniklinik Aachen. <b>C.\u00a0Kuppe<\/b>: A.\u00a0Finanzielle Interessen: C.\u00a0Kuppe gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Oberarzt Nephrologie, Uniklinik Aachen | Mitgliedschaft: Deutsche Gesellschaft f\u00fcr Nephrologie. <b>N.\u00a0T. Gaisa<\/b>: A.\u00a0Finanzielle Interessen: Finanzierung einer wissenschaftlichen Studie durch Janssen-Cilag. \u2013 Honorare f\u00fcr Fortbildungsveranstaltungen von AstraZeneca, Janssen-Cilag, Beyer, Zytomed. \u2013 Ad-boards f\u00fcr Janssen-Cilag, AstraZeneca. \u2013 B.\u00a0Nichtfinanzielle Interessen: Aktuell stellvertretende Leitung, sonst Ober\u00e4rztin, Leiterin Lehr- und Forschungsgebiet onkologische Pathologie, Institut f\u00fcr Pathologie Uniklinik RWTH Aachen, Aachen | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Pathologie, Deutsche Krebsgesellschaft, Internationale Akademie f\u00fcr Pathologie, BRIDGE e.\u202fV., DFBK e.\u202fV., IBCN | Sprecherin, Arbeitsgemeinschaft Uropathologie der Deutschen Gesellschaft f\u00fcr Pathologie; Hauptmandatstr\u00e4gerin der AOP in der Zertifizierungskommission der DKG f\u00fcr Harnblasen\u2011, Nieren- und Hodenkrebs. <b>M.\u00a0Saar<\/b>: A.\u00a0Finanzielle Interessen: Honorar und\/oder Kostenerstattung erhalten von: Pfizer Pharma GmbH, Janssen-Cilag GmbH, Bristol Myers, Squibb GmbH & Co KGaA, MSD Sharp & Dohme GmbH, Bayer Vital GmbH, Astellas Pharma GmbH, Merck,Healthcare Germany GmbH, Procept BioRobotics. \u2013 B.\u00a0Nichtfinanzielle Interessen: Klinikdirektor, Klinik f\u00fcr Urologie und Kinderurologie, Uniklinik RWTH Aachen, Aachen | Mitglied in nachstehenden wissenschaftlichen Gesellschaften\/Berufsverb\u00e4nden: Deutsche Gesellschaft f\u00fcr Urologie e.\u202fV. (DGU), European Association of Urology (EAU), German Association of Residents in Urology (GesRU), Deutsches Prostatakarzinom Konsortium e.\u202fV. (DPKK), S\u00fcdwestdeutsche Gesellschaft f\u00fcr Urologie e.\u202fV. (SWDGU), Deutscher Hochschul Verband, NRW Gesellschaft f\u00fcr Urologie e.\u202fV., Deutsche Gesellschaft f\u00fcr Roboter-assistierte Urologie e.\u202fV. (DGRU e.\u202fV.).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}